Brickell starts pivotal Phase III trial of drug candidate in U.S.
BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) has kicked off its final clinical trial in the U.S. for its anti-underarm sweating treatment.
In a statement, the Boulder company said it would start recruiting up to 350 subjects for its tests of Sofpironium Bromide for an eight-week period, but did not set a specific date for the trials to begin.
The Phase III trial, if successful, would pave the way for Brickell to get clearance to sell the product in the U.S. Such an approval is a milestone for clinical development companies that often survive the first few years without an approved drug from venture capital or doing contract research.
SPONSORED CONTENT
Select your Republic Services residential cart now!
In preparation for Republic Services becoming the primary provider of residential recycling, yard trimmings, and trash, residents should now select the best cart size and service schedule for their household needs.
The U.S. trials come weeks after Brickell and its development partner Kaken Pharmaceutical Co. Ltd. won sale approval in Japan.
© 2020 BizWest Media LLC
BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) has kicked off its final clinical trial in the U.S. for its anti-underarm sweating treatment.
In a statement, the Boulder company said it would start recruiting up to 350 subjects for its tests of Sofpironium Bromide for an eight-week period, but did not set a specific date for the trials to begin.
The Phase III trial, if successful, would pave the way for Brickell to get clearance to sell the product in the U.S. Such an approval is a milestone for clinical development companies that often survive the first…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!